HeartBeam (NASDAQ: BEAT) reported first-quarter 2026 operational and financial results highlighted by the launch of its initial commercial partnerships in key U.S. markets, progress in its heart attack detection and ambulatory ECG patch initiatives, and an April public offering that raised $11.5 million in gross proceeds. The company reported a first-quarter net loss of $4.7 million, improved from $5.5 million in the prior-year period, with research and development expenses declining year over year as HeartBeam continued advancing commercialization of its FDA-cleared cardiac monitoring platform and related growth initiatives.
NOTE TO INVESTORS: The latest news and updates relating to BEAT are available in the company’s newsroom at https://nnw.fm/BEAT
Please see full terms of use and disclaimers on the NetworkNewsWire website applicable to all content provided by NNW, wherever published or republished: http://NNW.fm/Disclaimer